Últimas noticias sobre Cogent Biosciences (NASDAQ:COGT) Bolsa

Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Cogent Biosciences Inc

BigBear.ai Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares are trading higher in Wednesday&#8217;s after-hours session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/01/b43015538/kevin-mcaleenan-appointed-ceo-of-bigbear-ai">chief executive transition</a>.
What Happened: BigBear.ai has appointed Kevin McAleenan as CEO and a member of the company&#8217;s board, effective as of Wednesday. McAleenan will replace Mandy Long, who is transitioning to an advisory role.
McAleenan currently serves as BigBear.ai&#8217;s president. He has extensive government experience and previously served as Acting Secretary of the U.S. Department of Homeland Security during President-elect Donald Trump&#8217;s first administration.
&#8220;Today marks an important next step for the business. The demand for differentiated artificial intelligence solutions to provide strategic advantage in government and business is strong and the combination of recent technological achievements and strategic contract awards have positioned BigBear.ai as a leading AI solutions provider focused on national security imperatives,&#8221; said Peter Cannito, chair of BigBear.ai&#8217;s board.
&#8220;Having served at the highest levels of government, Kevin brings an intimate understanding of current national security priorities and the challenges faced by our mission partners, providing BigBear.ai with a deep understanding of how artificial intelligence can be most effectively leveraged to maximize impact.&#8221;
See Also: <a href="https://www.benzinga.com/trading-ideas/previews/25/01/43014717/unitedhealth-group-q4-earnings-preview-first-report-since-insurance-ceos-murder">UnitedHealth Group Q4 Earnings Preview: First Report Since Insurance CEO&#8217;s Murder Comes With Questions On Company&#8217;s Future</a>
<h1 class="wp-block-heading">Is BBAI A Good Stock To Buy?</h1>
Wall Street analysts view BigBear.ai on the whole as a Buy, given the history of coverage over the past three months. Scott Buck from HC Wainwright &amp; Co. is the most optimistic, expecting a 133.33% rise in the stock in the coming year.
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, BigBear.ai rose 97.09%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price or underlying fundamentals, such as revenue, which rose 22.12% over the past year.
A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real-time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga Pro</a>. Try it for free.
BBAI Price Action: <a href="http://benzinga.com/quote/bbai">BigBear.ai shares</a> were up 4.42% at $3.54 after-hours Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: • <a href="https://www.benzinga.com/trading-ideas/previews/25/01/43014717/unitedhealth-group-q4-earnings-preview-first-report-since-insurance-ceos-murder">UnitedHealth Group Q4 Earnings Preview: First Report Since Insurance CEO&#8217;s Murder Comes With Questions On Company&#8217;s Future</a>
Photo: Shutterstock.

News

Management

After-Hours Center

Movers

Tech

BBAI

BigBear.AI Stock Surges On CEO Shake-Up: The Details

"Overall, based on factors within Orion's control and despite the strengthening FX headwind, we continue to expect modest growth in 2025, building upon the structurally improved returns our company has generated over the past several years," the company said.

Orion Says Commenced An Initiative In Q4 To Reduce Its Non-plant Workforce By ~6% And Expects To Realize $6M In Annualized Cost Savings In 2025

Weaker than anticipated Rubber segment volumes late in the fourth quarter and slightly less favorable Specialty segment mix were also factors and would have positioned the company at the lower end of guidance, excluding the items.

Guidance

Orion Now Expects 2024 Adjusted EBITDA To Be Nominally Below Guidance Range Of $305M - $315M, Due Primarily To Foreign Exchange Translation Impacts

SPX Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) has outperformed the market over the past 10 years by 10.51% on an annualized basis producing an average annual return of 21.88%. Currently, SPX Techs has a market capitalization of $6.87 billion. 
Buying $1000 In SPXC: If an investor had bought $1000 of SPXC stock 10 years ago, it would be worth $7,231.81 today based on a price of $148.29 for SPXC at the time of writing.
<h3>SPX Techs's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736977507_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

SPXC

Here's How Much $1000 Invested In SPX Techs 10 Years Ago Would Be Worth Today

The approximately 260-mile transmission project will support current and growing energy needs of the company's Wyoming customers, including data centers, while reducing dependence on third-party transmission systems.&nbsp;

Black Hills Says Wyoming Electric Utility Has Successfully Placed In Service The Initial 12-mile Segment

WIIM

SNAP

Snap and Meta shares are trading lower following a report suggesting Trump is considering an executive order hoping to save TikTok from a US ban.

<a href="https://www.washingtonpost.com/technology/2025/01/15/trump-tiktok-ban-executive-order/" title="https://www.washingtonpost.com/technology/2025/01/15/trump-tiktok-ban-executive-order/">https://www.washingtonpost.com/technology/2025/01/15/trump-tiktok-ban-executive-order/</a>

Social Media

General

Washington Post: 'Trump considers executive order hoping to 'save TikTok' from ban in U.S. law'

McKenna most recently served as President and Chief Executive Officer of Walmart International until her retirement in January 2024, where she was responsible for all aspects of Walmart's business outside the United States.

Delta Air Lines Board Adds Judith Mckenna As Its Newest Member, Effective February 7, 2025

Flowco Holdings Inc. ("Flowco"), a provider of production optimization, artificial lift and methane abatement solutions for the oil and natural gas industry, today announced the pricing of its initial public offering of 17,800,000 shares of its Class A common stock at a public offering price of $24.00 per share. In addition, the underwriters will have a 30-day option to purchase up to an additional 2,670,000 shares of Class A common stock from Flowco at the initial public offering price, less underwriting discounts and commissions. Flowco's Class A common stock is expected to begin trading on the New York Stock Exchange on January 16, 2025 under the ticker symbol "FLOC." The offering is expected to close on January 17, 2025, subject to the satisfaction of customary closing conditions.
Flowco intends to use the net proceeds that it receives from the proposed offering to redeem certain equity interests from certain non-affiliate holders, and with respect to the remainder, repay indebtedness under its existing credit agreement.

IPOs

FLOC

Flowco Announces The Pricing Of Its Initial Public Offering Of 17.8M Shares Of Its Class A Common Stock At A Public Offering Price Of $24.00 Per Share; Expected To Begin Trading On The New York Stock Exchange On January 16, 2025

Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) released its Q4 earnings on Wednesday, January 15, 2025 at 04:20 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Home BancShares missed estimated earnings by -4.0%, reporting an EPS of $0.5 versus an estimate of $0.52.
Revenue was up $12.75 million from the same period last year.
<h3>Earnings History Overview</h3>
The company missed on EPS by $0.03 in the previous quarter, leading to a 2.0% drop share price change the next day.
Here's a look at Home BancShares's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.53</td>
<td>0.49</td>
<td>0.46</td>
<td>0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.50</td>
<td>0.52</td>
<td>0.49</td>
<td>0.51</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>258.90M</td>
<td>247.21M</td>
<td>240.46M</td>
<td>243.07M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>258.00M</td>
<td>254.60M</td>
<td>246.39M</td>
<td>245.62M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Home BancShares <a href="https://www.benzinga.com/quote/HOMB/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

HOMB

Recap: Home BancShares Q4 Earnings

Rio Tinto Says Pilbara Iron Ore Operations Produced 328.0 Million Tonnes In 2024, With Shipments Of 328.6 Million Tonnes, Each 1% Lower Than 2023

<ul>
<li>Accelerates the tax-free spin-off of its Electronics business, now targeting November 1, 2025</li>
<li>DuPont to retain the Water business within its portfolio</li>
<li>Reaffirms fourth quarter and full year 2024 net sales, operating EBITDA and adjusted EPS financial guidance ahead of its February 11th earnings call</li>
</ul>
WILMINGTON,&nbsp;Del., Jan. 15, 2025 /PRNewswire/ -- DuPont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) today announced the acceleration of the separation of its Electronics business and is now targeting November 1, 2025 to complete the transaction. This decision recognizes the size and importance of Electronics to the overall shareholder value creation opportunity and DuPont's desire to complete the separation as quickly as possible.
Additionally, DuPont no longer intends to separate its Water business. The company evaluated all strategic alternatives and concluded the best path to generate value is for the Water business to remain in the DuPont portfolio. This also enhances DuPont's ability to continue optimizing its portfolio following the Electronics separation.
"We remain confident in the opportunity to create significant shareholder value through the separation of the Electronics business," said Ed Breen, DuPont Executive Chairman. "Achieving an independent Electronics company as soon as possible is the right decision for our shareholders."
"We remain excited about the value creation opportunity for DuPont following the Electronics separation," added Lori Koch, DuPont Chief Executive Officer. "The decision for Water to remain with DuPont provides the new organization with greater strategic flexibility over time and another high growth business alongside Healthcare. We continue to have conviction in the attractive outlook for Water and expect 2025 to be a strong year for the business."&nbsp;
Reaffirms Fourth Quarter and Full Year 2024 Financial Outlook
DuPont reaffirms its fourth quarter and full year 2024 financial guidance for net sales, operating EBITDA and adjusted EPS as provided on November 5, 2024 as part of its third quarter earnings release, including the expected continued improved performance in Water.
 &nbsp;

Dividends

DuPont Accelerates The Tax-Free Spin-Off Of Its Electronics Business, Now Targeting November 1, 2025; To Retain The Water Business Within Its Portfolio; Reaffirms Q4 And FY24 Financial Outlook

<a href="https://hindenburgresearch.com/gratitude/" title="https://hindenburgresearch.com/gratitude/">https://hindenburgresearch.com/gratitude/</a>

Short Sellers

CVNA

RBLX

SMCI

Hindenburg Research Founder Nate Anderson Said He Has Made The Decision To Disband The Firm

As a result, the Company has decided to voluntarily revise its historical adjusted operating income for the relevant periods, resulting in a decrease in after-tax adjusted operating income of $115 million or $0.31 per Common share for the nine months ended September 30, 2024, and $24 million or $0.07 per Common share for the nine months ended September 30, 2023, compared to previously reported amounts(1).&nbsp;
These revisions had no impact to GAAP net income, book value, statutory results, or the historical or expected future cash flows of these products.

Prudential Financial Says Identified An Immaterial Error During Q4 In Application Of Adjusted Operating Income - Filing

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 15 years by 7.09% on an annualized basis producing an average annual return of 18.86%. Currently, Amphenol has a market capitalization of $85.54 billion. 
Buying $1000 In APH: If an investor had bought $1000 of APH stock 15 years ago, it would be worth $12,870.75 today based on a price of $70.95 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736976607_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

NEXA

Nexa Resources Adopts New Dividend Policy; Targets Annual Dividend Of Up To 20% Of Free Cash Flow Pre-events, With Minimum Payment Of $0.08 Per Share

"Exceptional holiday demand and the effective execution of our strategic initiatives fueled our fourth-quarter outperformance, and gives us confidence that we will exceed our prior 2024 guidance,"&nbsp;stated Charlie Youakim, Sezzle Chairman and CEO.

SEZL

Sezzle Expects Exceeding 2024 Revenue And Income Guidance Provided In Conjunction With Its Q3 Earnings Release.

MetLife Responds To Report On Cyberattack, Says "We are aware of a cyberattack impacting Ecuador-based Fondo Genesis. As Fondo Genesis operates separately from MetLife's enterprise systems, this incident has not impacted any other parts of the MetLife business. Fondo Genesis is a financial services company operating only in Ecuador that is owned by Chilean pension manager ProVida, a subsidiary of MetLife."

Mandy Long will step down as Chief Executive Officer and from the Board of Directors, transitioning to serve as a Company advisor.
McAleenan currently serves as BigBear.ai's President.

BigBear.ai Appoints Kevin McAleenan As CEO And Member Of  Board, Effective January 15, 2025, Succeeding Mandy Long

Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.52 by 3.85 percent. The company reported quarterly sales of $258.36 million which beat the analyst consensus estimate of $256.70 million by 0.65 percent. This is a 5.19 percent increase over sales of $245.62 million the same period last year.

Earnings Beats

Earnings Misses

Home BancShares Q4 2024 Adj EPS $0.50 Misses $0.52 Estimate, Sales $258.36M Beat $256.70M Estimate

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Cogent Biosciences (COGT – Research Report), with a p...

Cogent Biosciences (COGT) Receives a Buy from Piper Sandler

Cogent Biosciences (COGT) reported positive updated data from Part 1 of the company's ongoing Phase 2 APEX clinical trial evaluating bezuclastinib ...

Cogent Biosciences announces updated data from ongoing Phase 2 APEX trial

Cogent Biosciences (COGT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Ne...

Strong Efficacy and Safety Profile of Cogent Biosciences' Bezu in Adv SM Outshines Competitors

Cogent Biosciences (COGT) announced updated clinical results from the Open Label Extension OLE, portion of SUMMIT, a clinical trial evaluating bezu...

Cogent Biosciences announces updates results from SUMMIT

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Cogent Biosciences (COGT – Research Report), retaining the price target of $16.00...

Promising Market Potential for Cogent Biosciences: A Buy Rating Backed by Efficacy and Safety of Bezuclasinib

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Cogent Biosciences (COGT – Research Report), with a price t...

Cogent Biosciences (COGT) Gets a Buy from J.P. Morgan

Cogent Biosciences (COGT) highlighted the company's key 2025 milestones ahead of its presentation at J.P. Morgan's 43rd annual healthcare conferenc...

Cogent Biosciences highlighted key 2025 milestones

08:11 EST Cogent Biosciences (COGT) up 10% at $8.14 after disclosing insider buy Published first on TheFly – the ultimate source for real-time, mar...

Cogent Biosciences up 10% at $8.14 after disclosing insider buy

In a regulatory filing, Cogent Biosciences (COGT) disclosed that its Chief Commercial Officer Cole Pinnow bought 43.8K shares of common stock on Ja...

Cogent Biosciences exec buys $332K in common stock

Cogent and ModivCare gain after insider purchases

AVDL

COGT

MODV

Press Releases

Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Health Care

Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis

Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics

Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Analyst Ratings

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Comments

Cogent Biosciences

Noticias

Últimas noticias sobre Cogent Biosciences (NASDAQ:COGT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL